본문 바로가기
HOME> 논문 > 논문 검색상세

논문 상세정보

The Journal of antimicrobial chemotherapy v.72 no.2, 2017년, pp.486 - 489   SCI SCIE
본 등재정보는 저널의 등재정보를 참고하여 보여주는 베타서비스로 정확한 논문의 등재여부는 등재기관에 확인하시기 바랍니다.

Daclatasvir 30 mg/day is the correct dose for patients taking atazanavir/cobicistat

Smolders, E. J. (Department of Pharmacy, Radboud Institute for Health Sciences (RHIS) and Radboud University Medical Center, Nijmegen, The Netherlands ) ; Colbers, E. P. H. (Department of Pharmacy, Radboud Institute for Health Sciences (RHIS) and Radboud University Medical Center, Nijmegen, The Netherlands ) ; de Kanter, C. T. M. M. (Department of Pharmacy, University Medical Center Utrecht, Utrecht, The Netherlands ) ; Velthoven-Graafland, K. (Department of Pharmacy, Radboud Institute for Health Sciences (RHIS) and Radboud University Medical Center, Nijmegen, The Netherlands ) ; Drenth, J. P. H. (Department of Gastroenterology and Hepatology, Radboud University Medical Center, Nijmegen, The Netherlands ) ; Burger, D. M. (Department of Pharmacy, Radboud Institute for Health Sciences (RHIS) and Radboud University Medical Center, Nijmegen, The Netherlands ) ;
  • 초록  

    Background Atazanavir is boosted with the cytochrome P450 (CYP) 3A4 inhibitor ritonavir. When combined with the CYP3A4 substrate daclatasvir, the daclatasvir dosage should be reduced from 60 to 30 mg once daily. Recently, cobicistat was licensed as a CYP3A booster and used with atazanavir. Objectives To determine whether the fixed-dose combination of atazanavir/cobicistat has an influence on daclatasvir pharmacokinetics comparable to that of the separate agents atazanavir and ritonavir. Methods A prospective, open-label, two-period, randomized, cross-over trial was performed in 16 healthy subjects (NCT02565888). Treatment consisted of 300/100 mg of atazanavir/ritonavir plus 30 mg of daclatasvir once daily (reference) and a second period of 300/150 mg of atazanavir/cobicistat plus 30 mg of daclatasvir once daily (test). A 24 h pharmacokinetic, steady-state curve was recorded for all drugs. Geometric mean ratios (GMRs) with 90% CI were calculated for daclatasvir and atazanavir AUC τ  and C max to compare the effect of both treatments (test versus reference). Laboratory safety and adverse events were evaluated throughout the trial. Results All 16 healthy subjects completed the study. Median (range) age and BMI were 48.5 (21–55) years and 24.5 (19.0–29.2) kg/m 2 , respectively. Pharmacokinetic parameters of ritonavir and cobicistat were comparable to those in the literature. The GMRs (90% CI) of daclatasvir AUC τ and C max (test versus reference) were 101% (92%–111%) and 97% (89%–106%), respectively. Atazanavir GMRs (90% CI) of AUC τ and C max were 82% (75%–79%) and 74% (68%–81%), respectively. No serious adverse events were reported. Conclusions Atazanavir/cobicistat and atazanavir/ritonavir had a similar influence on daclatasvir pharmacokinetics in healthy volunteers. Daclatasvir at 30 mg once daily is the correct dose when combined with atazanavir/cobicistat.


 활용도 분석

  • 상세보기

    amChart 영역
  • 원문보기

    amChart 영역

원문보기

무료다운로드
  • 원문이 없습니다.
유료다운로드

유료 다운로드의 경우 해당 사이트의 정책에 따라 신규 회원가입, 로그인, 유료 구매 등이 필요할 수 있습니다. 해당 사이트에서 발생하는 귀하의 모든 정보활동은 NDSL의 서비스 정책과 무관합니다.

원문복사신청을 하시면, 일부 해외 인쇄학술지의 경우 외국학술지지원센터(FRIC)에서
무료 원문복사 서비스를 제공합니다.

NDSL에서는 해당 원문을 복사서비스하고 있습니다. 위의 원문복사신청 또는 장바구니 담기를 통하여 원문복사서비스 이용이 가능합니다.

이 논문과 함께 출판된 논문 + 더보기